Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PRCY - ANY BODY HAS ANY NEWS ON THESE -- Ignore unavailable to you. Want to Upgrade?

To: Chris Nevil who wrote (373)	6/17/1998 2:33:00 PM
From: Coha	Read Replies (1) \| Respond to of 670

The revenue stream should be a decent reflection of what we can expect down the road. Along with Bard, there should also be a kick-in from Humatech as well as the cosmetic and hair restoration products. The Humatech acquisition cost $1.5 mil in cash and 1.5 mil in common. Hence it is a double hit both in assets and dilution. If they take the full hit this qtr, bk value/share will drop to the $1.15 range (est - I don't know what the bk on Humatech is so this may be overly conservative) from $1.45 the previous qtr and cash value/share will drop to .68 (est) from .89. I'm basing this on an est $.8 mil operating loss for the qtr combined with the $1.5 mil acquisition. Dr. Leavitt runs Medical Hair Restoration. Look it up in your phone book. It's the 3rd largest (I think) national network of hair restoration clinics in the U.S., behind Bosley and HRI(?). See this article for more: hair-transplants.net or medicalhairrestoration.com Procyte has 4 (?) sales reps currently located in the major states - NY, FL, TX, and CA to market the cosmetic and hair products. These products are totally separate from the wound healing products distributed by Bard. All margins flow directly to the company on the niche stuff. The bottom line is the market continues to value the stock (significantly) below bk value while the company begins to dramatically ramp revenue and the CEO buys more shares. Coha